| Chemical identity |
Racemic mixture of two enantiomers: (S)-citalopram (active) + (R)-citalopram (less active/possibly antagonistic) |
Pure (S)-enantiomer (escitalopram) |
| Potency |
Lower potency – higher dose needed to achieve the same serotonin‑reuptake inhibition |
More potent – effective at lower doses (≈ 10 mg/day) |
| Typical starting dose |
20 mg/day (some guidelines start lower, 10 mg, then titrate) |
10 mg/day, usually increased to 20 mg if needed |
| Maximum recommended dose |
40 mg/day (some countries limit to 20 mg due to QT‑interval concerns) |
20 mg/day (often the upper limit in many countries) |
| Half‑life |
~35 hours |
~27 hours |
| Metabolism |
CYP2C19, CYP3A4, CYP2D6 |
CYP2C19, CYP3A4 (slightly less involvement of CYP2D6) |
| Side‑effect profile |
GI upset, headache, sexual dysfunction, dry mouth, tremor, drowsiness |
Similar but often reported as milder (especially GI). Sexual side‑effects remain, but some patients find escitalopram better tolerated. |
| QT‑interval effect |
Dose‑dependent prolongation; risk higher at > 20 mg/day |
Also dose‑dependent but generally considered less arrhythmogenic than citalopram at comparable doses. |
| Drug interactions |
Significant interactions with CYP2C19 inhibitors (e.g., fluoxetine) or inducers (e.g., rifampin). |
Similar interactions, but because it’s only the S‑enantiomer, the magnitude can differ slightly. |
| FDA/EMA labeling |
Approved for major depressive disorder, generalized anxiety disorder, and others. |
Same indications. Some labels mention “may be preferred when lower doses are desired.” |
| Clinical evidence |
Extensive long‑term data (over 20 years). |
15‑+ year data, but slightly newer; still robust. |
| Cost & availability |
Often cheaper (generic available in many countries). |
Usually more expensive, though generics are now available in many places. |
| Patient preference |
Some patients tolerate the racemic mix fine; others develop GI upset or sedation. |
Many patients report fewer GI side‑effects and smoother titration. |